Inhibikase Therapeutics Reports on Shareholder Vote Matters
Ticker: IKT · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1750149
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: IKAS
TL;DR
IKAS held a shareholder vote on June 7th. Details to follow.
AI Summary
Inhibikase Therapeutics, Inc. filed an 8-K on June 10, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 7, 2024. The company, incorporated in Delaware, is involved in biological products, specifically excluding diagnostics, and is headquartered in Atlanta, Georgia.
Why It Matters
This filing indicates that Inhibikase Therapeutics has held or is preparing for a shareholder vote, which could pertain to significant corporate actions or governance changes.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- June 7, 2024 (date) — Date of earliest event reported
- June 10, 2024 (date) — Date of report
- Atlanta, Georgia (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing states that it is a 'Submission of Matters to a Vote of Security Holders' but does not detail the specific matters in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported was on June 7, 2024.
What is the principal business of Inhibikase Therapeutics, Inc.?
The company's Standard Industrial Classification is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Where are Inhibikase Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st.
Filing Stats: 670 words · 3 min read · ~2 pages · Grade level 11.7 · Accepted 2024-06-10 16:05:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
Filing Documents
- d850029d8k.htm (8-K) — 36KB
- 0001193125-24-158318.txt ( ) — 159KB
- ikt-20240607.xsd (EX-101.SCH) — 3KB
- ikt-20240607_lab.xml (EX-101.LAB) — 18KB
- ikt-20240607_pre.xml (EX-101.PRE) — 11KB
- d850029d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 10, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer